Overview

Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma

Status:
Not yet recruiting

Trial end date:
2024-10-30

Target enrollment:

Participant gender:

Summary

This is a prospective, multicenter, phase III study of Tucidinostat, Azacitidine combined with CHOP versus CHOP in patients with untreated peripheral T-cell lymphoma

Phase:

Phase 3

Details

Lead Sponsor:

Peking Union Medical College Hospital

Treatments:

Azacitidine